Market Overview

UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking

Share:
Related VRTX
Vertex's Cystic Fibrosis Drug Given The Okay For Pediatric Use In Europe
How To Trade The JPMorgan Healthcare Conference
Which Biotech Stocks Could Surprise To The Upside On Earnings? (Investor's Business Daily)

In a report published Friday, Credit Suisse analyst Ravi Mehrotra reiterated a Neutral rating on Vertex Pharmaceuticals (NASDAQ: VRTX), and raised the price target from $48.00 to $80.00.

In the report, Mehrotra noted, “Raising our CF franchise estimates. VRTX announced positive PII data for VX-661 + Kalydeco in cystic fibrosis (CF) patients with the homozygous F508del mutation. To reflect our increased expectations, we are raising our WW peak sales for VRTX's CF franchise to $4.0B (from $2.9B) in 2022. We note that these estimates serve as placeholders until we dig deeper into the factors driving the CF franchise's potential. We raise our DCF-derived TP to $80 (from $48). High doses of VX-661 in combination with Kalydeco shows statistically significant improvement in lung function. The relative increases in FEV1 (vs. placebo) for the 100mg and 150mg VX-661 arms were 9.0% and 7.5% respectively.”

Vertex Pharmaceuticals closed on Thursday at $52.87.

Latest Ratings for VRTX

DateFirmActionFromTo
Jan 2018Bank of AmericaUpgradesNeutralBuy
Dec 2017Deutsche BankInitiates Coverage OnBuy
Sep 2017DA DavidsonInitiates Coverage OnBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings

 

Related Articles (VRTX)

View Comments and Join the Discussion!